Controlled Hookworm Infection for Medication-free Maintenance in Patients with Ulcerative Colitis: A Pilot, Double-blind, Randomized Control Trial

• Published in: Inflammatory bowel diseases Vol. 30; no. 5; pp. 735 - 745
• Main Authors: Mules, Thomas C, Lavender, Brittany, Maclean, Kate, Vacca, Francesco, Noble, Sophia-Louise, Yumnam, Bibek, Te Kawa, Tama, Cait, Alissa, Tang, Jeffry, O'Sullivan, David, Gasser, Olivier, Stanley, James, Le Gros, Graham, Camberis, Mali, Inns, Stephen
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 02.05.2024
• Subjects: Adult; Animals; Clinical Research; Colitis, Ulcerative - drug therapy; Double-Blind Method; Feasibility Studies; Feces - parasitology; Female; Hookworm Infections - drug therapy; Humans; Leukocyte L1 Antigen Complex - analysis; Male; Mesalamine - therapeutic use; Middle Aged; Pilot Projects; Quality of Life; Remission Induction; Treatment Outcome; clinical trial; ulcerative colitis; helminth; hookworm; inflammatory bowel disease
• ISSN: 1078-0998; 1536-4844
• DOI: 10.1093/ibd/izad110

Human hookworm has been proposed as a treatment for ulcerative colitis (UC). This pilot study assessed the feasibility of a full-scale randomized control trial examining hookworm to maintain clinical remission in patients with UC. Twenty patients with UC in disease remission (Simple Clinical Colitis Activity Index [SCCAI] ≤4 and fecal calprotectin (fCal) <100 ug/g) and only on 5-aminosalicylate received 30 hookworm larvae or placebo. Participants stopped 5-aminosalicylate after 12 weeks. Participants were monitored for up to 52 weeks and exited the study if they had a UC flare (SCCAI ≥5 and fCal ≥200 µg/g). The primary outcome was difference in rates of clinical remission at week 52. Differences were assessed for quality of life (QoL) and feasibility aspects including recruitment, safety, effectiveness of blinding, and viability of the hookworm infection. At 52 weeks, 4 of 10 (40%) participants in the hookworm group and 5 of 10 (50%) participants in the placebo group had maintained clinical remission (odds ratio, 0.67; 95% CI, 0.11-3.92). Median time to flare in the hookworm group was 231 days (interquartile range [IQR], 98-365) and 259 days for placebo (IQR, 132-365). Blinding was quite successful in the placebo group (Bang's blinding index 0.22; 95% CI, -0.21 to 1) but less successful in the hookworm group (0.70; 95% CI, 0.37-1.0). Almost all participants in the hookworm group had detectable eggs in their faeces (90%; 95% CI, 0.60-0.98), and all participants in this group developed eosinophilia (peak eosinophilia 4.35 × 10^9/L; IQR, 2.80-6.68). Adverse events experienced were generally mild, and there was no significant difference in QoL. A full-scale randomized control trial examining hookworm therapy as a maintenance treatment in patients with UC appears feasible.